Medetomidine hydrochloride is a potent, highly selective α2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively). It is an imidazole compound. Medetomidine hydrochloride shows greater selectivity over α1-adrenoceptors than clonidine and UK 14,304 (1620-, 220- and 300-fold respectively). In addition, it influences the adrenergic system by mimicking the action of adrenergic neurotransmitters.
An α2-Adrenergic agonist. Sedative; analgesic.
Medetomidine is a selective α2-adrenoceptor agonist, with Ki of 1.08 nM, exhibts 1620-fold selectivity over α1-adrenoceptor
ChEBI: Medetomidine hydrochloride is a hydrochloride.
medetomidine is a selective α2-adrenoceptor agonist, with ki of 1.08 nm, exhibts 1620-fold selectivity over α1-adrenoceptor.
After intramuscular injection, medetomidine is rapidly and almost completely absorbed at the site of injection and its pharmacokinetics are very similar to that observed after intravenous injection. Maximum plasma concentrations are reached within 15 to 20 minutes. Estimated plasma half-life is 1.2 hours for dogs and 1.5 hours for cats. Medetomidine is mainly oxidised in the liver, while a small amount is methylated in the kidney. Metabolites are primarily excreted in urine.
Medetomidine hydrochloride is an alpha-2 adrenoreceptor agonist. Symptoms after absorption may involve clinical effects, including dose dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically.
